Afficher la notice abrégée

Cross-sectional study on exhaled nitric oxide in relation to upper airway inflammatory disorders with regard to asthma and perennial sensitization

dc.rights.licenseopenen_US
dc.contributor.authorKRANTZ, Christina
dc.contributor.authorACCORDINI, Simone
dc.contributor.authorALVING, Kjell
dc.contributor.authorCORSICO, Angelo G.
dc.contributor.authorDEMOLY, Pascal
dc.contributor.authorFERREIRA, Diogenes S.
dc.contributor.authorFORSBERG, Bertil
dc.contributor.authorGARCIA-AYMERICH, Judith
dc.contributor.authorGISLASON, Thorarinn
dc.contributor.authorHEINRICH, Joachim
dc.contributor.authorJOGI, Rain
dc.contributor.authorJOHANNESSEN, Ane
dc.contributor.authorLEYNAERT, Benedicte
dc.contributor.authorMARCON, Alessandro
dc.contributor.authorMARTINEZ-MORATALLA ROVIRA, Jesus
dc.contributor.authorNERPIN, Elisabet
dc.contributor.authorNOWAK, Dennis
dc.contributor.authorOLIN, Anna-Carin
dc.contributor.authorOLIVIERI, Mario
dc.contributor.authorPEREIRA-VEGA, Antonio
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorRAHERISON-SEMJEN, Chantal
dc.contributor.authorGOMEZ REAL, Francisco
dc.contributor.authorSIGSGAARD, Torben
dc.contributor.authorSQUILLACIOTI, Guilia
dc.contributor.authorJANSON, Christer
dc.contributor.authorMALINOVSCHI, Andrei
dc.date.accessioned2023-03-10T13:58:46Z
dc.date.available2023-03-10T13:58:46Z
dc.date.issued2022-02
dc.identifier.issn1365-2222en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/172255
dc.description.abstractEnBackground Fractional exhaled nitric oxide (FeNO) is a well-known marker of type-2 inflammation. FeNO is elevated in asthma and allergic rhinitis, with IgE sensitization as a major determinant. Objective We aimed to see whether there was an independent association between upper airway inflammatory disorders (UAID) and FeNO, after adjustment for asthma and sensitization, in a multi-centre population-based study. Methods A total of 741 subjects with current asthma and 4155 non-asthmatic subjects participating in the second follow-up of the European Community Respiratory Health Survey (ECRHS III) underwent FeNO measurements. Sensitization status was based on measurement of IgE against airborne allergens; information on asthma, UAID and medication was collected through interview-led questionnaires. Independent associations between UAID and FeNO were assessed in adjusted multivariate regression models and test for interaction with perennial sensitization and asthma on the relation between UAID and FeNO were made. Results UAID were associated with higher FeNO after adjusting for perennial sensitization, asthma and other confounders: with 4.4 (0.9–7.9) % higher FeNO in relation to current rhinitis and 4.8 (0.7–9.2) % higher FeNO in relation to rhinoconjunctivitis. A significant interaction with perennial sensitization was found in the relationship between current rhinitis and FeNO (p = .03) and between rhinoconjunctivitis and FeNO (p = .03). After stratification by asthma and perennial sensitization, the association between current rhinitis and FeNO remained in non-asthmatic subjects with perennial sensitization, with 12.1 (0.2–25.5) % higher FeNO in subjects with current rhinitis than in those without. Conclusions & Clinical Relevance Current rhinitis and rhinoconjunctivitis was associated with higher FeNO, with an interaction with perennial sensitization. This further highlights the concept of united airway disease, with correlations between symptoms and inflammation in the upper and lower airways and that sensitization needs to be accounted for in the relation between FeNO and rhinitis.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.enasthma
dc.subject.enexhaled nitric oxide
dc.subject.enFeNO
dc.subject.ennasal polyposis
dc.subject.enpopulation-based
dc.subject.enrhinitis
dc.title.enCross-sectional study on exhaled nitric oxide in relation to upper airway inflammatory disorders with regard to asthma and perennial sensitization
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/cea.14019en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34536262en_US
bordeaux.journalClinical and Experimental Allergyen_US
bordeaux.page297-311en_US
bordeaux.volume52en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamEPICENE_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20and%20Experimental%20Allergy&rft.date=2022-02&rft.volume=52&rft.issue=2&rft.spage=297-311&rft.epage=297-311&rft.eissn=1365-2222&rft.issn=1365-2222&rft.au=KRANTZ,%20Christina&ACCORDINI,%20Simone&ALVING,%20Kjell&CORSICO,%20Angelo%20G.&DEMOLY,%20Pascal&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
license_rdf
Taille:
811octets
Format:
application/rdf+xml
Voir/Ouvrir
Thumbnail
Nom:
BPH_CEA_2022_Krantz.pdf
Taille:
837.6Ko
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée